Protagonist Therapeutics Stock (NASDAQ: PTGX)

Protagonist Therapeutics

PROTAGONIST THERAPEUTICS INC

Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.

D-Wave Quantum Inc.

Equities

Mid Cap

News

Movers

Trading Ideas

HSAI

IONQ

ORLA

PTGX

QBTS

RGTI

SMTC

Mid-cap stocks were top performers last week. D-Wave, Protagonist, Veren, IonQ, Rigetti, Semtech, Orla Mining, and Hesai all saw significant gains.

D-Wave Quantum And IonQ Are Among Top Mid-Cap Stock Gainers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio?

GileadSciences.Shutterstock

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

ASAN

AVPT

DRIO

GILD

OKUR

ORCL

Gilead Sciences To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday

Redfin, housing

Intraday Update

KTOS

LZMH

MLYS

PLAY

RDFN

STAA

TRVI

TSCO

Redfin, Mineralys Therapeutics, Trevi Therapeutics And Other Big Stocks Moving Higher On Monday

Protagonist Therapeutics, Inc. - Common Stock

Protagonist Therapeutics Inc

Press Releases

Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual Meeting

Clear Street Launches Healthcare & Biotechnology Equity Research

Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025

Protagonist Therapeutics Reports Granting of Inducement Awards

Protagonist to Host Investor Event with KOL Insights on Polycythemia Vera (PV) and the Hepcidin Mimetic Rusfertide in New York on February 6, 2025

Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

Icotrokinra Clinical Study Results Demonstrate Its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis

Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis

Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025

CGEM

CRGX

DCTH

ELVN

ERAS

IMTX

IPSC

JANX

MLTX

NUVB

TYO:4502

YMAB

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals

Arcellx

Akero Therapeutics

Alvotech

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals

Biohaven

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Amicus Therapeutics

ImmunityBio

Immunovant

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

Metsera

NewAmsterdam Pharma Company N.V. - Ordinary Shares

NewAmsterdam Pharma Co

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Avidity Biosciences

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals

Rhythm Pharmaceuticals, Inc. - Common Stock

Rhythm Pharmaceuticals

Soleno Therapeutics

Scholar Rock Holding Corporation - Common Stock

Scholar Rock Holding

SpringWorks Therapeutics, Inc. - common stock

SpringWorks Therapeutics

Twist Bioscience Corporation - Common Stock

Twist Bioscience

Veracyte

Viking Therapeutics

Zai Lab Limited - American Depositary Shares

Zai Lab

Wedbush

Truist Securities

BMO Capital

HC Wainwright & Co.

Citizens Capital Markets

Comments

Protagonist Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga